922731-04-2
Chemical Structure
Esomeprazole-d6 sodium
Synonym(s): (S)-Omeprazole-d6 sodium; (-)-Omeprazole-d6 sodium
- CAS No.: 922731-04-2
- Formula:C17H13D6N3NaO3S
- Molecular Weight:374.44
IUPAC Name: 3-ethynyl-4-methoxybenzoic acid
InChIKey: HVAJOLFRLWQQQL-ZGKVGPQDSA-N
SMILES: CC(C(OC([2H])([2H])[2H])=C(C=N1)C)=C1C[S@@](C(NC2=C3)=NC2=CC=C3OC([2H])([2H])[2H])=O.[Na]
Biological Activity: Esomeprazole-d6 sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Esomeprazole-d6 sodium | Esomeprazole-d6 sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Esomeprazole sodium (Standard) | ≥98% | Esomeprazole (sodium) (Standard) is the analytical standard of Esomeprazole (sodium). This product is intended for research and analytical applications. Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H+-ATPases. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Esomeprazole sodium | 99.88% | Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H+-ATPases. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46. [Content Brief]
- [3]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16. [Content Brief]
